Introduction: Bone metastases are the most common cause of cancer-related pain in various primary malignant tumors, most often, breast and prostate. 188Re-hydroxyethylidene diphosphonate (188Re-HEDP) is a new and less expensive bone seeking radiopharmaceutical with favorable physical characteristics of the radionuclide such as short half life of 16.9h, maximal β energy of ...

Skeletal metastases or secondary cancerous lesions in bone, are common in patients suffering from breast, lung and prostate cancer, in the advanced stage of the disease. These metastatic lesions in skeleton, often lead to excruciating pain and other related symptoms such as: lack of mobility, neurological deficits, depression, anxiety, anger, fear of death etc., which adversely affect the quali...

INTRODUCTION In oncological patients, life quality can be greatly impaired by the presence of painful bone metastases, as standard forms of treatment often achieve inadequate palliation. The aim of our study was to evaluate the clinical efficacy of radiofrequency ablation (RFA) with respect to pain relief in patients with refractory bone metastases or who are ineligible to conventional treatmen...

introduction one of the important applications of nuclear physics in medicine is the use of radioactive elements as radiopharmaceuticals. metastatic bone disease is the most common form of malignant bone tumors. samarium-153-ethylene diamine tetramethylene phosphonate (153sm-edtmp) as a radiopharmaceutical is used for pain palliation. this radiopharmaceutical usually emits beta particles, which...

UNLABELLED This study evaluated the effects of low-dose cisplatin plus 89Sr versus 89Sr alone in the treatment of painful bone metastases from prostate cancer, addressing both pain palliation and cytostatic effects. METHODS Seventy patients with metastatic hormone-refractory prostate cancer were randomized into 2 groups: One group (arm A) received 148 MBq 89Sr plus 50 mg/m(2) cisplatin, and t...

Developing new bone pain palliation agents is a mandate in handling end-stage cancer patients around the world. Possibly, Lu-177 ethylenediaminetetramethylene phosphonic acid ((177)Lu-EDTMP) is a therapeutic agent which can be widely used in bone palliation therapy. In this study, (177)Lu-EDTMP complex was prepared successfully using synthesized EDTMP ligand and (177)LuCl3. Lu-177 chloride was ...

treatment of bone metastases comprises over 10% of the workload of a radiation-oncology center. bone metastases produce severe pain and immobility, necessitate narcotic use, and reduce the quality of life. a good palliative treatment must be complete, free from side effects and fast; thus we decided to evaluate strontium-89 (89sr) effectivity for palliation of breast and prostate cancer bone me...